MAIA Reaches Enrollment Milestone Of 65 In Phase 3 THIO-104 For Ateganosine In Lung Cancer

MAIA Biotechnology reached its target enrollment of 65 patients in the Phase 3 THIO-104 trial evaluating Ateganosine as a third-line treatment for advanced non-small cell lung cancer. Completion of enrollment is a positive clinical-development milestone, but efficacy and safety results remain the key valuation catalysts.